A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence
Enrolling By Invitation
18-99 years
All
Phase
3
1 participants needed
1 Location
Brief description of study
This is a study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Her2-Positive Breast Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Males and Females, Age 18 or over, confirmed invasive breast carcinoma
Updated on
01 Aug 2024.
Study ID: 848504
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
